Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.

Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).

That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).

The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.

Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.

The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.

Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.

The late-stage biotechnology company, which is developing the coronavirus medicine leronlimab, announced last week that it had filed a comprehensive application for uplisting on NASDAQ. The company announced that it believes that its application satisfies the myriad listing requirements of the NASDAQ Capital Market.

The Chief Executive Officer and President of the company Nader Pourhassan stated that while it is true that the entire process is expected to take many weeks, CytoDyn is hopeful of success in this matter.

He went on to state that a listing on NASDAQ will not only provide shareholders with more liquidity but also give CytoDyn much bigger access to fresh capital. It is a significant development for the company, and the market participants realized it as well. After the announcement was made, the stock rallied by as much as 50%. Investors could do well to keep an eye on the stock this week.

While the rally following this announcement was a welcome relief for the company, it is important to point out that earlier on in the week, the stock has fallen considerably following a setback. Last Monday, the company announced that the United States Food and Drug Administration handed CytoDyn a refusal to file a letter with regards to the usage of leronlimab to treat HIV.

However, at the same time, investors should be noted that the company did announce that it is confident of furnishing the agency with all the further details that have been demanded. It is one of the penny stocks that have performed remarkably well this year so far, and investors could keep an eye on it.

That being said, it should be noted that despite the gains recorded by many stocks, most of those stocks are still considerably lower than the all-time highs. In such a situation, it could be worthwhile for investors to take a closer look at some of the strongest and more stable cannabis companies in the industry. Here is a look at three pot stocks that made significant moves in May and could be tracked by investors at this point.

1. HEXO Stock Jumps Ahead of Earnings

HEXO Corp (TSX:HEXO) (NYSE:HEXO) is one of those cannabis companies which have had a particularly tough time over the past year or so. However, the stock has emerged as one of the bigger gainers among pot stocks in recent trading sessions. The Hexo stock has gained as much as 120% over the course of the past month. The company is all set to release its financial results for the fiscal third quarter on Thursday, and hence, it could be a big week for the stock.

The recent surge in the Hexo stock may have come as a major boost to investors, but it should be noted that over the past year, it recorded considerable losses. The beaten-down nature of the stock may have contributed to the stock becoming more attractive for investors. However, the trajectory of the Hexo stock in the near term is going to depend a lot on its third-quarter earnings.

The company had made a loss of $298 million in the previous quarter, and while it is almost certain that it is going to make a loss again, the size of the loss is going to be keenly watched. Additionally, any writedowns are also going to be harmful to the stock. Investors should also keep an eye on sales growth.

2 Organigram gains Momentum on Value Buying

Organigram Holdings (TSX:OGI) (NASDAQ:OGI) is another pot stock that has made significant gains in the past month. Since May 13, the stock has gained as much as 80%. In April, the company announced its fiscal second-quarter results, but it had been a disappointment.

Revenues dropped by 13.7% year on year to hit CA$23.2 million, and losses widened to CA$6.8 million from CA$6.4 million in the prior-year period. However, one significant cause for optimism for Organigram investors is the fact that in the second quarter, cannabis 2.0 products made up as much as 13% of its revenue. That has opened up a whole new opportunity for the company.

Wholesale cannabis revenue made up 24% of the net, and that is again a new source of revenue. The company blamed the lower volumes of flower as well as cannabis oil for the drop in sales. Organigram reported cash and cash equivalents of CA$41.1 million as of February 29. Considering the fact that it has burned CA$25 million in the past six months, investors should not use that the cash balance does not paint a pretty picture.

3 Aphria Recovers Following Solid Earnings

Aphria (TSX:APHA) (NYSE:APHA), on the other hand, managed to perform relatively well in its fiscal third quarter. The net sales rose by as much as 19.7% sequentially to hit CA$144.4 million, and more importantly, the company also managed to record a profit for the third time in four quarters. On top of that, it should be noted that although the Canadian cannabis company spends CA$124.4 million on its operations in the nine months trailing that quarter, it still reported a cash balance of CA$515 million.

The performance seems to have buoyed market participants as well, and the stock has rallied by as much as 75% since the middle of May. One of the most important things that investors are going to be looking into is whether Aphria is going to be able to maintain its profitability.

However, due to the turmoil caused by the coronavirus pandemic, it might prove difficult. That being said, it should be noted that the pandemic is going to have an equally damaging effect across the sector.

 JOIN US NOW: For Details Contact us at info@tradersinsights.com

 Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy Sorrento Therapeutics Inc (NASDAQ: SRNE) yesterday (march 18th) at $2.67. Now look at the price of the stock – its up 15% at $3.23 from our buy price. This is how easy money they made. If you had invested $5,000 in SRNE, it could had been moved up to $5,750.  It’s not yet late, join us at info@tradersinsights.com

97.7% of patients receiving 300 mg of Cosentyx achieved PASI 75 (75% improvement in symptoms) at week 12 while 87% achieved PASI 90 (90% improvement) at week 16.

For the 150 mg dose, 87.8% achieved PASI 75 and 66.4% achieved PASI 90 at week 12.

The FDA approved Cosentyx for the indication in January 2015.

Shares are down 3% premarket on light volume.

Have you seen the article Forbes wrote about the ASDN Flying Passenger Drone and its technology?

Office Depot (NYSE:ODP) announces a new strategic collaboration with Alibaba (NYSE:BABA).

The collaboration is expected to leverage the companies’ respective strengths to serve U.S. SMBs, including Office Depot’s deep relationships with more than 10M U.S. business customers.

The company says the goal of the collaboration is to empower U.S. small- and medium-sized businesses to grow by tapping into the global B2B e-commerce marketplace.

ODP +10.96% premarket to $3.95.

Why Investors Are Calling ASDN the TPC of the Sky!

Have you seen the article Forbes wrote about the ASDN Flying Passenger Drone and its technology?

Clovis Oncology (NASDAQ:CLVS) announces that Rubraca (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Rucaparib is the first PARP inhibitor licensed for an ovarian cancer treatment indication in the EU and is now the first to be available for both treatment and maintenance treatment among eligible patients.

Why Investors Are Calling ASDN the CLVS of the Sky!

Clovis Oncology intends to launch Rubraca in other European countries to follow in 2019 and 2020.

Shares are up 5% premarket.

NVIDIA Corporation (NVDA) remains nearly 50 percent below its 52-week high set back in October, while the SMH semiconductor ETF is around 10 percent from sealing its own new record.

Todd Gordon , founder of TradingAnalysis.com, sees a bigger break lower for the semis stock.

“You can see that we’re in a fairly well established downtrend here in Nvidia,” said Gordon. “I don’t even think we’ve retraced a third of what we’ve lost since the 2018 high… not even a quarter of what we’ve lost from the high. That shows relative weakness.”

Why AMZN is Overvalued and Why ASDN Could Outperform NVDA in 2019

The Nasdaq 100 QQQ ETF, by comparison, has retraced around 61 percent of its decline from highs in September, while the SMH ETF has seen a retracement of more than three-quarters its loss, Gordon adds. The QQQ ETF is less than 8 percent from its highs.

“On top of that, what we’ll see is Nvidia has traced out the classic three wave corrective pattern,” he said. “The primary trend is clearly down at this point. We’ve bounced from $130, you’ve gone up, the volume was ok, it wasn’t great on the bounce, sold back down on a gap here and now we’re coming back for a three wave move.”

Nvidia looks to be in the middle of an Elliott Wave movement, a technical theory that maps out prices moves based on investor behavior. In this formation, it could see the last of the three corrective waves that typically form, meaning further downside.

“I want to just try to get down and retest these lows around the $130 level,” he added.

A move down to $130 represents a 16 percent decline from Thursday’s close.

To play for a move to the downside, Gordon is buying the March 150/145 put spread for $1.25. This is a bearish bet that targets a move to $145 in the new two weeks.

Arcadia (Nasdaq: RKDA) shares closed rose $2.65 to close at $8.05, and at one point rose as high as $10.40, nearly double the previous day’s close of $5.40.

The company will focus in the federally legal markets for cannabis products, which are forecast for tremendous growth, said Arcadia chief financial officer Matt Plavan. Plavan has been named president of Arcadia Specialty Genomics, the subsidiary of Arcadia that will specialize in the standardization of cannabis genetic matieral for quality, climate resiliency and yield.

Jeff Bezos would probably be interested in the tech that ASDN has to offer

He anticipates the 50-employee company will add six scientists this year and another six employees in the next 18 months.

Most of the growth from hemp production is expected to be related to cannabidiol oils, or CBD, which are believed to have nutritional and pharmaceutical properties.

Plavan said projections for hemp growth are “staggering.” The Hemp Business Journal estimates that the hemp CBD market totaled $190 million in 2018, which is a high number considering it didn’t exist as a category five years ago, Plavan said. He cited estimates that the CBD market is expected to reach between $2 billion and $22 billion by 2022.

“Even at the low end of the very large range, that is a staggering rate of growth,” he said.

Net sales were down 4.7%; excluding the 53rd week in 2017, they were up 0.1%. Comparable sales rose 0.1%.

Comparable sales dropped 1.6% in Full-Price due to softer traffic in full-line stores. Off-Price comparable sales rose 4%, in line with company guidance.

Gross profit margin of 35.1% was down 33 basis points due to higher markdowns and elevated promotions amid the softer full-price sales.

Have you seen the article Forbes wrote about the ASDN Flying Passenger Drone and its technology?

Net earnings rose to $248M from $151M mainly due to tax reform; EBIT dipped to $333M from $350M (in both periods making up 7.6% of net sales).

For 2019, it’s guiding to net sales growth of 1-2%, with mid- to high-single-digit growth in credit card revenues; EBIT of $915M-$970M, with a margin of 5.9-6.1%, and EPS of $3.65-$3.90 (vs. consensus for $3.67).

Petrobras (PBR) is expanding its divestment program and has “bold” plans for future sales, CEO Roberto Castillo Branco said in today’s earnings conference call.

Shallow water and onshore fields are among the first on the block, while PBR hopes to complete the sale of its TAG pipeline unit “soon” and several options are being considered for the future of distribution unit Petrobras Distribuidora, executives said.

Why Investors Are Calling ASDN the TPC of the Sky!

In some of his most assertive comments on the need to slim down the big company, Castillo Branco said debt reduction could occur through various initiatives, the most important of which are “a more aggressive divestment program and getting out of assets where we’re not a natural owner. Really, get out – not sell part of the asset.”

The company can reduce its ratio of net debt to EBITDA to 1.5x or even to 1x with the help of divestments, the CEO said; the ratio at the end of Q4 was 2.34x.

Revenues grew nearly 19% Y/Y to $91.1M, and gross margin (non-GAAP) rose to 28.6% from last quarter’s 24%.

The company logged a gain on a non-GAAP basis vs. an adjusted loss the previous quarter.

EBITDA came to $10.5M, up $6.2M Q/Q.

Have you seen the article Forbes wrote about the ASDN Flying Passenger Drone and its technology?

Liquidity was $76.7M, up $12M from last quarter; restricted cash was $11.1M, up $5.9M from last quarter.

For Q1, it’s guiding to $77M-$82M in revenues (vs. consensus for $79.7M); gross margin of 23-27% (non-GAAP); operating expenses of $24M-$25M; and EPS of -$0.17 to -$0.08 (below consensus for -$0.07).

AMC Entertainment (NYSE:AMC) turns to a profit in Q4 after seeing attendance increase 5%.

Why Investors Are Calling ASDN the TPC of the Sky!

The average ticket price at AMC fell to $9.26 from $9.92 with the new subscription service in play.

AMC’s adjusted EBITDA margin of 18.7% during the quarter was lower than last year’s mark of 20.3%, but ahead of the consensus estimate of 16.9%.

AMC +8.82% AH to $15.30.